改善了埃索诺菲尔性食管炎的结果,并提高了药物持有率
Nathan T Kolasinski1,2, Eric A Pasman2,3, Cade M Nylund1,2
1Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.
Medicines (Basel, Switzerland)
|April 26, 2024
概括
药物占有率 (MPR) 的坚持显著影响了eosinophilic食道炎 (EoE) 的结果. 0.7或更高的MPR与更好的组织学缓解和更少的症状有关,可能减少重复内镜检查的需要.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学 是一个学科.
- 临床研究 临床研究
背景情况:
- 生性食道炎 (EoE) 是一种慢性炎症状况.
- 治疗不坚持是EoE疾病活性的一个关键因素.
- 药物持有率 (MPR) 是一个验证的衡量标准,用于评估药物服药.
研究的目的:
- 调查MPR与EoE治疗结果之间的相关性.
- 确定一个最佳的MPR值,以实现EOE的组织学缓解.
- 评估MPR对临床结果的影响,如食和食物影响.
主要方法:
- 使用已建立的EoE注册表 (2005-2020) 进行回顾性队列研究.
- 确定治疗周期的MPR计算.
- 对组织学缓解 (<15 eos/hpf) 和临床结果的医疗记录的评估.
主要成果:
- 与非缓解期 (0.63) 相比,在经历了组织学缓解的治疗期 (0.91) 中,MPR的平均值明显高于非缓解期 (0.63).
- 0.7的MPR切点显示出最佳的灵敏度和特异性,可以预测组织学缓解.
- 高于0.7的MPR与组织学缓解的几率增加和缺食症,食物受损,狭窄和食道扩张的几率降低有关.
结论:
- MPR是评估对 EoE 管理的遵守的一个有价值的工具.
- 一个MPR≥0.7与改善的治疗结果有关.
- 将MPR评估纳入临床实践可能有助于优化EoE管理并减少不必要的程序.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
279
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
279
01:26Peptic Ulcer Disease IV: Management
89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
01:23Inhaled Medications
255
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
255
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
73
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
73
01:26COPD: Management Using Bronchodilators and Corticosteroids
198
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
198
01:19Antiasthma Drugs: Leukotriene Modifiers
281
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
281